Abstract
We evaluated the possibility that distinct proteolytic pathways contribute to the down-regulation of a novel (ε) or conventional (α) isoform of protein kinase C (PKC) in nonimmortalized human fibroblasts. Inhibitors of calpains and other cysteine proteinases, vesicle trafficking, or lysosomal proteolysis did not affect the down-regulation of PKC-α or -ε produced by bryostatin 1 (Bryo). Lactacystin (Lacta) and certain terminal aldehyde tripeptides or tetrapeptides, which selectively inhibit the proteasome, preserved substantial PKC-α and -ε protein from down-regulation by Bryo or phorbol-12-myristate-13-acetate. Lacta preserved active kinasein vivo, as shown by the retention of Bryo-induced autophosphorylated PKC-α. Concomitant with down-regulation, Bryo produced PKC-α and -ε species that were larger than the native proteins (80 and 90 kDa, respectively). Western blot analysis showed that the larger PKC-α species were ubiquitinylated. Treatment with Bryo plus Lacta synergistically increased multiubiquitinylated PKC-α, as expected if Bryo induces ubiquitinylation of PKC-α and Lacta blocks its degradation. Bryo also produced a 76-kDa, nonphosphorylated form of PKC-α and an 86-kDa form of PKC-ε. Phosphatase inhibitors decreased production of 76- and 86-kDa PKC-α and -ε by Bryo and preserved 80- and 90-kDa PKC-α and -ε, respectively. Our results suggest that the down-modulation of PKC-α and -ε occurs principally via the ubiquitin/proteasome pathway. Dephosphorylation seems to predispose PKC to ubiquitinylation.
Footnotes
-
Send reprint requests to: Dr. Jeffrey B. Smith, Department of Pharmacology and Toxicology, Volker Hall, G133E, 1670 University Boulevard, Birmingham, AL 35294-0019. E-mail:jeff.smith{at}ccc.uab.edu
-
↵1 Lee, H.-W., and Smith, J. B., unpublished observations.
-
This work was supported by National Institutes of Health Grant HL44408 (G.B.S.); by Outstanding Investigator Grant CA44344–01-08 (G.R.P.) from the United States National Cancer Institute, Divison of Cancer Treatment, Diagnosis Centers; and by the Department of Health and Human Services, and The Arizona Disease Control Research Commission.
- Abbreviations:
- PKC
- protein kinase C
- AcLLMal
- N-acetyl-Leu-Leu-methional
- AcLLNal
- N-acetyl-Leu-Leu-norleucinal
- BFA
- brefeldin A
- Bryo
- bryostatin 1
- DAG
- diacylglycerol
- DMEM
- Dulbecco’s modified Eagle’s medium
- Lacta
- lactacystin
- LB
- lysis buffer
- PAGE
- polyacrylamide gel electrophoresis
- PMA
- phorbol-12-myristate-13-acetate
- SDS
- sodium dodecyl sulfate
- TBS
- Tris-buffered salt solution
- TRH
- thyrotropin-releasing hormone
- Ub
- ubiquitin
- ZGLALal
- benzyloxycarbonyl-Gly-Leu-Ala-leucinal
- ZGLALol
- benzyloxycarbonyl-Gly-Leu-Ala-leucinol
- Received October 16, 1996.
- Accepted December 4, 1996.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|